APMA DENOUNCES CMS DECISION ON SAME-DAY CARE

CMS’s 2027 Medicare Physician Fee Schedule final rule reduces payment by 20% for certain same-day services billed with modifier 25 alongside a 0-day global procedure, effective January 1, 2027; the proposed reduction was 50%. APMA says the cut will disproportionately affect podiatry, could pressure solo, small and rural practices, and may limit access to essential foot and ankle care, including for patients with diabetes. APMA plans to work with the Same Day Care Coalition to urge Congress to halt implementation.

Analysis

The market-relevant risk is not a broad healthcare earnings shock; it is a targeted reimbursement squeeze whose impact depends on how much affected practices rely on same-day E/M claims paired with 0-day global procedures. APMA’s disproportionate-impact claim is advocacy, not quantified exposure. Before treating this as a podiatry-sector thesis, verify claims-level frequency, affected allowed amounts, and whether practices can legitimately change workflows or coding without shifting care to another visit.

Second-order effects could include fewer same-day evaluations, more follow-up visits, or consolidation among small and rural practices. Any shift that delays diabetic foot-ulcer treatment could raise downstream care needs, but that is a longer-dated and uncertain Medicare cost offset—not an immediate earnings catalyst for a tradeable company. Larger practice operators could gain share if local competitors exit, though the article provides no evidence that this benefit is material to any public company.

Near term, the likely market effect is limited absent a clearly exposed listed operator. The 1–3 month catalyst is lobbying for congressional intervention or implementation guidance; the structural question over 6–18 months is whether access, practice counts, and coding behavior change. A broader signal would be CMS extending payment edits to other specialties or services. The thesis weakens if Congress delays implementation, CMS narrows the affected claims, or actual claims data show low exposure and little change in access.

Key Decisions for Investors

• No broad healthcare short or options position: the rule is narrowly scoped, and the supplied information does not identify a listed company with measurable exposure.
• Set a watch item for CMS implementation guidance and congressional action before January 1, 2027; reassess only after affected-claim frequency and payment exposure are independently quantified.
• For healthcare-services diligence, monitor podiatry and small-practice operators for changes in same-day billing, visit volumes, practice closures, and consolidation. Consider a relative long in scaled operators only if filings confirm exposure and credible share gains.
• Falsification triggers: a legislative delay or CMS narrowing that materially reduces affected claims; alternatively, evidence of sustained access deterioration or meaningful earnings guidance cuts at demonstrably exposed operators would raise the risk case.